PathAI Appoints Biopharma Executive and Digital Pathology Leader Micha

PathAI, a leading provider of AI-powered technology for advancing pathology research, announced that it has appointed translational medicine and digital pathology leader, Michael C. Montalto, PhD, as Chief Science Officer. Dr. Montalto joins PathAI from Bristol-Myers Squibb (BMS), where he was Vice President and Head of Translational Sciences, Translational Medicine. "We are incredibly fortunate and excited to welcome Mike onto our leadership team," said Andrew Beck, MD, PhD, co-founder and Chief Executive Officer of PathAI. "Mike brings tremendous experience developing digital pathology diagnostic products and driving cutting-edge translational research in a large biopharmaceutical setting. We are thrilled to be working with Mike at PathAI to use AI-powered pathology to support the development of new therapies and diagnostics for patients."